Occupational Therapists in Davenport, FL Accepting Medicare

9 Occupational Therapists found. Showing 1 - 9

Su-ling Luciano Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 131 Webb Dr Ste D, Davenport, FL 33837 Phone: 863-547-6673

Gina Bongirno, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 40124 Highway 27 Ste 103, Davenport, FL 33837 Phone: 863-419-2500

Mrs. Siobhan Maire Veronica Smith Occupational Therapist Medicare: Medicare Enrolled Practice Location: 221 Almeria Way, Davenport, FL 33837 Phone: 321-270-3586

Alexis Brackins, OTD, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 40124 Highway 27 Ste 103, Davenport, FL 33837 Phone: 863-419-2500

Wendy Rodriguez, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2520 Sand Mine Rd, Davenport, FL 33897 Phone: 407-910-2941

Marlon J Pinkney Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 153 Villavista Ct, Davenport, FL 33896 Phone: 321-544-9314

Dr. Valerie S. Trinidad, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 40124 Us-27 #103, Davenport, FL 33837 Phone: 863-419-2500

Possabilities Therapy Services Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 327 Kettering Rd, Davenport, FL 33897 Phone: 863-273-1456

Nature's Place Therapyservices, Inc. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1316 South Blvd W, Davenport, FL 33837 Phone: 863-421-0556    Fax: 863-421-0467

News Archive

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.

Medical Care Technologies to include HVS as add-on to its Tele-Health Suite

Medical Care Technologies Inc. today announced that it has been developing its latest medical device technology - Heart Vital Signs ("HVS") to be included as an add-on to its Tele-Health™ Suite. Remote cardiac monitoring technologies allow home electrocardiographic (ECG) monitoring of patients with suspected cardiac arrhythmias or at risk for developing arrhythmias.

AACN to present Marguerite Rodgers Kinney Award for a Distinguished Career to MGH's Sally Millar

The American Association of Critical-Care Nurses will present the Marguerite Rodgers Kinney Award for a Distinguished Career to Sally Millar, RN, MBA. She will receive this Visionary Leadership Award for contributions to AACN's mission and vision at the 2013 National Teaching Institute & Critical Care Exposition, Boston, May 18-23.

XJB-5-131 compound suppresses symptoms of Huntington's in mice

There's new hope in the fight against Huntington's disease. A group of researchers that includes scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have designed a compound that suppresses symptoms of the devastating disease in mice.

Read more Medical News

› Verified 4 days ago